Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinase A as a Structure Surrogate.
Russell A JudgeAnil VasudevanVictoria E ScottGricelda H SimlerSteve D PrattMarian T NamovicC Brent PutmanAna AguirreVincent S StollMulugeta MamoSteven I SwannSteven C CassarConnie R FaltynekKaren L KageJanel M Boyce-RustayAdrian D HobsonPublished in: Chembiochem : a European journal of chemical biology (2018)
We describe the design, synthesis, and structure-activity relationships (SARs) of a series of 2-aminobenzothiazole inhibitors of Rho kinases (ROCKs) 1 and 2, which were optimized to low nanomolar potencies by use of protein kinase A (PKA) as a structure surrogate to guide compound design. A subset of these molecules also showed robust activity in a cell-based myosin phosphatase assay and in a mechanical hyperalgesia in vivo pain model.